```html

Zollinger‑Ellison Disease (Type I Hypergastrinemia)

Overview

Zollinger‑Ellison disease (ZED) is a rare disorder in which one or more tumors (gastrinomas) form in the pancreas or duodenum and secrete large amounts of the hormone gastrin. The excess gastrin stimulates the stomach lining to produce **excess gastric acid**, leading to severe peptic ulcers, diarrhea, and malabsorption.

It is classified as type I hypergastrinemia because the elevated gastrin levels are driven by a gastrin‑producing tumor rather than by physiological stimuli such as low stomach pH.

• Incidence: Approximately 0.5–2 cases per million people per year.
• Prevalence: About 1–3 cases per 100,000 individuals worldwide.
• Age: Most patients are diagnosed between ages 30 and 60, but it can occur at any age.
• Gender: Slight male predominance (≈55 % men).

Because the disease is rare, many patients experience a delay of 2–5 years from symptom onset to diagnosis.<sup>1</sup>

Symptoms

The hallmark of ZED is the combination of **acid‑related gastrointestinal symptoms** and **tumor‑related effects**. Symptoms may be intermittent early on and become more constant as the tumor grows.

Digestive Symptoms

• Refractory Peptic Ulcers: Ulcers that fail to heal with standard therapy; often multiple and located beyond the duodenum (e.g., jejunum).
• Abdominal Pain: Burning or cramping pain, usually relieved temporarily by antacids.
• Heartburn & Acid Reflux: Due to excess stomach acid spilling into the esophagus.
• Diarrhea: Occurs in up to 70 % of patients; can be watery, fatty (steatorrhea), or contain blood.
• Nausea & Vomiting: Frequently triggered by high‑acid meals.
• Weight Loss: From malabsorption and chronic diarrhea.

Systemic/Non‑Digestive Symptoms

• Fatigue: Resulting from anemia, nutrient deficiencies, or chronic illness.
• Iron‑Deficiency Anemia: Due to chronic intestinal bleeding from ulcers.
• Osteoporosis: Long‑standing malabsorption of calcium and vitamin D.
• Flushing or Skin Changes: Rare, but may occur with metastatic gastrinomas that secrete other hormones.

Causes and Risk Factors

ZED is a **neuroendocrine tumor (NET)** arising from G‑cells that normally produce gastrin. The precise cause of these tumors is not fully understood, but several factors increase risk.

Genetic Causes

• Multiple Endocrine Neoplasia type 1 (MEN‑1): An autosomal‑dominant syndrome caused by mutations in the MEN1 gene. About 20–30 % of ZED patients have MEN‑1.<sup>2</sup>
• Familial Gastrinoma Syndromes: Rare inherited gastrinoma clusters not linked to MEN‑1.

Acquired Risk Factors

• Age: Incidence rises after age 30.
• Chronic Atrophic Gastritis: Long‑standing inflammation may predispose to neuroendocrine hyperplasia, though this link is weaker than with MEN‑1.
• Environmental: No definitive lifestyle or environmental exposures have been proven, but smoking may increase NET risk in general.<sup>3</sup>

Diagnosis

Because symptoms mimic common GI disorders, a structured work‑up is essential.

1. Laboratory Tests

• Fasting Serum Gastrin: Levels > 1000 pg/mL (or > 10‑fold upper limit) are highly suggestive. However, gastrin can be modestly elevated in chronic proton‑pump inhibitor (PPI) use, renal failure, or atrophic gastritis, so the test is done after PPI washout (usually 7 days).<sup>4</sup>
• Secretin Stimulation Test: Administration of secretin paradoxically raises gastrin levels > 120 pg/mL in ZED (normal response is a decrease).
• Chromogranin A: A neuroendocrine marker, often elevated in gastrinomas.
• Complete Metabolic Panel: To assess electrolytes, renal function, calcium, and vitamin D.

2. Imaging Studies

• Endoscopic Ultrasound (EUS): Highly sensitive for detecting small pancreatic or duodenal tumors (≈85 % detection).
• Multiphasic CT or MRI: Provides anatomic detail and evaluates for metastatic disease (particularly liver).
• Somatostatin Receptor Scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Functional imaging that highlights neuroendocrine tumor tissue.

3. Endoscopy

• Upper Endoscopy (EGD): Visualizes ulcer location, severity, and can obtain biopsies to rule out H. pylori or malignancy.
• Enteroscopy or Capsule Endoscopy: Used when ulcers are distal (jejunum) and not seen on standard EGD.

Diagnostic Criteria (Summary)

1. Fasting gastrin > 1000 pg/mL (or > 10× ULN) after PPI washout.
2. Positive secretin stimulation test.
3. Imaging demonstrating a gastrinoma (pancreatic, duodenal, or gastric).
4. Exclusion of other causes of hypergastrinemia (e.g., chronic atrophic gastritis, renal failure).

Treatment Options

Management aims to control acid hypersecretion, remove or shrink the tumor, and prevent complications.

Medical Therapy – Acid Control

• Proton‑Pump Inhibitors (PPIs): High‑dose PPIs (e.g., omeprazole 40–80 mg daily or equivalent) are the first line; they normalize gastric pH in > 95 % of patients.<sup>5</sup>
• Histamine‑2 Receptor Antagonists (H2RAs): May be added if PPIs are insufficient.
• Long‑term acid suppression is usually required for life, even after tumor resection.

Surgical Management

• Localized Tumors: Enucleation (removal of the tumor only) or pancreatic/duodenal segmental resection. Curative in 60‑70 % of sporadic gastrinomas.
• Multifocal or MEN‑1 Associated Tumors: More complex; often a pancreaticoduodenectomy (Whipple procedure) or duodenotomy with tumor excision.
• Liver Metastases: Resection, radiofrequency ablation, or hepatic arterial embolization may be considered.

Medical Oncology – For Unresectable or Metastatic Disease

• Somatostatin Analogs: Octreotide or lanreotide reduce gastrin secretion and can stabilize tumor growth.
• Targeted Therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have shown benefit in advanced pancreatic NETs.
• Peptide‑Receptor Radionuclide Therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to tumor cells expressing somatostatin receptors.
• Chemotherapy: Reserved for high‑grade, rapidly progressive disease (e.g., streptozocin‑based regimens).

Lifestyle & Supportive Measures

• Avoid irritants that increase acid (caffeine, alcohol, tobacco, spicy foods).
• Small, frequent meals; low‑fat diet to reduce duodenal irritation.
• Supplementation with calcium, vitamin D, and iron if deficiencies develop.
• Regular bone density testing (DEXA) because chronic acid hypersecretion can impair calcium absorption.

Living with Zollinger‑Ellison Disease (type I hypergastrinemia)

While ZED is a chronic condition, many patients lead active lives with proper management.

Daily Management Tips

1. Take PPIs exactly as prescribed. Missing doses can cause rebound acid hypersecretion and ulcer recurrence.
2. Schedule regular follow‑up labs. Check fasting gastrin, calcium, vitamin D, and complete blood count every 6–12 months.
3. Monitor symptoms. Keep a diary of abdominal pain, stool frequency, and any weight changes; share with your clinician.
4. Stay up‑to‑date with imaging. Annual or biennial CT/MRI or Octreoscan is recommended for tumor surveillance, especially if you have MEN‑1.
5. Vaccinations. If you undergo splenectomy during surgery, get pneumococcal, Haemophilus influenzae type b, and meningococcal vaccines.
6. Psychosocial support. Joining a NET or ZED patient group can reduce anxiety and provide practical tips.

Work & Travel

• Carry a medication card with your diagnosis, PPI dose, and emergency contact.
• When flying, keep PPIs in your carry‑on to avoid temperature extremes.
• Request a low‑acid diet or avoid buffet‑style meals that may contain trigger foods.

Prevention

Because ZED is primarily tumor‑driven, primary prevention is limited. However, you can reduce overall neuroendocrine tumor risk and limit complications:

• Do not smoke. Smoking is an established risk factor for many pancreatic tumors.
• Limit alcohol consumption. Heavy drinking can exacerbate ulcer disease.
• Maintain a healthy weight. Obesity is associated with higher incidence of pancreatic neoplasms.
• Screen at‑risk relatives. If you have MEN‑1, first‑degree relatives should undergo genetic counseling and periodic gastrin testing.

Complications

If untreated or poorly controlled, ZED can lead to serious health problems:

• Perforated Ulcer: A hole in the stomach or intestinal wall leading to peritonitis.
• Gastrointestinal Bleeding: From erosive ulcers; can cause anemia or require transfusion.
• Intestinal Obstruction: Scarring from multiple ulcers may block the bowel.
• Metastatic Disease: Approximately 25‑40 % develop liver metastases; prognosis worsens significantly.
• Gastric Carcinoma: Chronic acid exposure raises the risk of gastric adenocarcinoma.
• Nutrient Malabsorption: Leads to deficiencies (iron, calcium, fat‑soluble vitamins) and secondary osteoporosis.

When to Seek Emergency Care

References

1. Mayo Clinic – Zollinger‑Ellison Syndrome
2. MEN1 and Gastrinomas – NCBI
3. National Cancer Institute – Neuroendocrine Tumors
4. CDC – Pancreatic Cancer Overview
5. Cleveland Clinic – Zollinger‑Ellison Syndrome

```